-
EP4081527
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4081527
| EP4081527 - THE COMBINATION OF CYCLIN DEPENDENT KINASE 7 INHIBITOR AND IMMUNOTHERAPY FOR TREATMENT OF CANCER [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 30.09.2022 Database last updated on 14.11.2024 | |
| Former | The international publication has been made Status updated on 07.07.2021 | Most recent event Tooltip | 15.07.2024 | Change - representative | Applicant(s) | For all designated states Dana-Farber Cancer Institute, Inc. 450 Brookline Avenue Boston, MA 02215 / US | For all designated states New York University 70 Washington Square South New York, NY 10012-1091 / US | [2022/44] | Inventor(s) | 01 /
GRAY, Nathanael, S. 26 Greenview Avenue Boston, MA 02130 / US | 02 /
WONG, Kwok-kin 49 Columbia Road Arlington, MA 02474 / US | 03 /
ZHANG, Hua 30 Waterside Plaza, Apt 32h New York, NY 10010 / US | 04 /
ROSS, Camilla, Laulund Christensen 9 Leonard Avenue Cambridge, MA 02139 / US | [2022/44] | Representative(s) | Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB | [N/P] |
| Former [2022/44] | HGF HGF Limited 1 City Walk Leeds LS11 9DX / GB | Application number, filing date | 20908219.7 | 16.12.2020 | [2022/44] | WO2020US65267 | Priority number, date | US201962953376P | 24.12.2019 Original published format: US 201962953376 P | [2022/44] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021133601 | Date: | 01.07.2021 | Language: | EN | [2021/26] | Type: | A1 Application with search report | No.: | EP4081527 | Date: | 02.11.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 01.07.2021 takes the place of the publication of the European patent application. | [2022/44] | Search report(s) | International search report - published on: | US | 01.07.2021 | (Supplementary) European search report - dispatched on: | EP | 12.12.2023 | Classification | IPC: | A61K31/4162, C07D487/04, A61P35/00, C07D487/10, A61K31/454, A61K45/06 | [2024/02] | CPC: |
A61K31/4162 (EP,US);
A61K31/454 (EP);
A61K31/7048 (US);
A61K33/243 (US);
A61K39/3955 (US);
A61K45/06 (EP);
A61P11/00 (US);
A61P35/00 (EP,US);
C07D487/04 (EP);
C07D487/10 (EP)
(-)
| C-Set: |
A61K31/4162, A61K2300/00 (EP);
A61K31/454, A61K2300/00 (EP) |
| Former IPC [2022/44] | C07D487/04, A61P35/00, A61K31/4162, C07D487/10, A61K31/454, A61K45/06 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/44] | Title | German: | KOMBINATION EINES CYCLINABHÄNGIGEN KINASE-7-INHIBITORS UND EINER IMMUNTHERAPIE ZUR BEHANDLUNG VON KREBS | [2022/44] | English: | THE COMBINATION OF CYCLIN DEPENDENT KINASE 7 INHIBITOR AND IMMUNOTHERAPY FOR TREATMENT OF CANCER | [2022/44] | French: | ASSOCIATION D'UN INHIBITEUR DE KINASE 7 DÉPENDANTE DE CYCLINES ET D'UNE IMMUNOTHÉRAPIE POUR LE TRAITEMENT DU CANCER | [2022/44] | Entry into regional phase | 22.07.2022 | National basic fee paid | 22.07.2022 | Search fee paid | 22.07.2022 | Designation fee(s) paid | 22.07.2022 | Examination fee paid | Examination procedure | 22.07.2022 | Examination requested [2022/44] | 08.07.2024 | Amendment by applicant (claims and/or description) | 08.07.2024 | Date on which the examining division has become responsible | Fees paid | Renewal fee | 22.07.2022 | Renewal fee patent year 03 | 15.11.2023 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XYI]WO2016105528 (DANA FARBER CANCER INST INC [US]) [X] 1-4,6,11,13,15 * p. 206, cl. 56, middle; cl. 1, 70-86 ; [00266]; [0019]; 00289] * [Y] 1-15 [I] 1-15; | [XY]WO2017160717 (MEMORIAL SLOAN KETTERING CANCER CENTER [US]) [X] 1-3,6,11,13,15 * claims, in particular cl. 1, 9, 21, 36; Fig. 15; example 2. * [Y] 1-15; | [XP]WO2020100944 (UBE INDUSTRIES [JP]) [XP] 1-3,6,11,13,15 * claim 5 p. 89/90; example 7; cl. 19-20 *; | [XP]WO2020140098 (DANA FARBER CANCER INST INC [US]) [XP] 1-3,6,11,13,15 * claim 1; compounds on p. 179/180; [00259], 00237, e.g. with alemtuzumab (p. 120), pembrolizumab (p. 122) *; | [E]WO2021016388 (DANA FARBER CANCER INST INC [US]) [E] 1-4,6,11,13,15 * compounds on p. 160-165, 152; §0232 *; | [E]WO2021026109 (DANA FARBER CANCER INST INC [US]) [E] 1-3,6,13,15* claims 1, 34, 37-41; [0146] * | International search | [A]US2009221632 (FANCELLI DANIELE [IT], et al) [A] 2 * ; paragraph [0769] *; | [X]US2019055248 (GRAY NATHANAEL S [US], et al) [X] 1-14, 34-35, 50-54 * ; abstract; paragraphs [0017], [0019], [0084], [0107]-[0115], [0117]-[0124], [0189], [0215], [0217], [0222], [0246], [0292], [0304], [0336], [0346], [0362], [0378], [0394], [0402], [0404], [0448], [0452], [0482], [0487], [0511] *; | [A] - BRASCA, M et al., "Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles:ldentification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing", Bioorganic and Medicinal Chemistry, (20100301), vol. 18, no. 5, doi:10.1016/j.bmc. 2010.01.04 2, pages 1844 - 1853, XP026925757 [A] 2 DOI: http://dx.doi.org/10.1016/j.bmc.2010.01.042 |